Skip to main content
Clinical Trials/NCT00980876
NCT00980876
Completed
Phase 3

Multicentric, Double Blind, Randomized, Parallel Comparative Study Between Ciprofloxacin HCl 2 mg/mL + Hydrocortisone 10 mg/mL Ear Suspension and Cipro HC®, for the Assessment of Efficacy and Safety in Patients With Otitis Externa.

Farmoquimica S.A.1 site in 1 country224 target enrollmentApril 2012

Overview

Phase
Phase 3
Intervention
Cipro HC
Conditions
Otitis Externa
Sponsor
Farmoquimica S.A.
Enrollment
224
Locations
1
Primary Endpoint
Cure (reduced pain, swelling and otorrhea)
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The objective of this study is to compare the efficacy and safety profiles of the test product containing 2 mg/mL ciprofloxacin hydrochloride associated with 10 mg/mL of hydrocortisone with the reference product Cipro HC®, in patients with acute otitis externa.

Detailed Description

Phase III, non inferiority, multicentric, controlled, single blind, parallel-group, randomized study. Population: 224 patients with external otitis , men and women aged between 1 - 70 years. Primary endpoint: The primary endpoint of this study is the elimination of pain, swelling and otorrhea (cure). Secondary endpoint: The endpoint will be the identification of the side effects of medication use.

Registry
clinicaltrials.gov
Start Date
April 2012
End Date
January 2015
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Informed of the nature of the study and given written informed consent;
  • Patients with acute otitis externa;
  • Intact tympanic membrane.

Exclusion Criteria

  • Known allergy or sensitivity to Ciprofloxacin Hydrochloride and Hydrocortisone;
  • Patient has the tympanic membrane not intact;
  • Bilateral Acute Otitis Externa;
  • Pregnant or lactating patients;
  • Overt fungal Acute Otitis Externa;
  • Other diseases of the ear
  • Current Infection requiring systemic antimicrobial therapy.
  • Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.

Arms & Interventions

Cipro HC

Reference product

Intervention: Cipro HC

Ciprofloxacin HCl and Hydrocortisone

Test product

Intervention: Ciprofloxacin HCl and Hydrocortisone

Outcomes

Primary Outcomes

Cure (reduced pain, swelling and otorrhea)

Time Frame: 7 days

Secondary Outcomes

  • Identification of possible side effects(7 days)

Study Sites (1)

Loading locations...

Similar Trials